^
    3d
    Triptorelin for Early Diagnosis of Hypogonadotrophic Hypogonadism (clinicaltrials.gov)
    P=N/A, N=48, Enrolling by invitation, Hospital de Niños R. Gutierrez de Buenos Aires
    New trial
    |
    triptorelin
    6d
    Study on Human Bioequivalence of Triprerelin Acetate for Injection (clinicaltrials.gov)
    P1, N=120, Recruiting, The Affiliated Hospital of Qingdao University
    New P1 trial
    |
    triptorelin
    8d
    Study on the role of probiotics in alleviating leuprolide-induced perimenopausal syndrome in assisted reproductive therapy (ChiCTR2400089614)
    P=N/A, N=150, Not yet recruiting, Reproductive Hospital Affiliated to Jiangxi University of Traditional Chinese Medicine; Reproductive Hospital Affiliated to Jiangxi University of Trad
    New trial
    |
    leuprolide acetate for depot suspension
    17d
    REAL6T: A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy (clinicaltrials.gov)
    P=N/A, N=167, Completed, Ipsen | Recruiting --> Completed | N=300 --> 167
    Trial completion • Enrollment change
    |
    triptorelin
    19d
    Injection Free IVF (clinicaltrials.gov)
    P2, N=0, Withdrawn, Insel Gruppe AG, University Hospital Bern | N=112 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    26d
    RATIONAL-PCS: Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC) (clinicaltrials.gov)
    P2, N=162, Not yet recruiting, Ontario Clinical Oncology Group (OCOG)
    New P2 trial • Metastases
    |
    Eligard (leuprolide acetate)
    1m
    YATAGARASU: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Janssen Pharmaceutical K.K. | Trial completion date: Sep 2025 --> Dec 2027
    Trial completion date • Combination therapy • Metastases
    |
    AR (Androgen receptor)
    |
    AR positive • AR expression
    |
    Erleada (apalutamide) • goserelin acetate
    1m
    Menopausal Sleep Fragmentation and Body Fat Gain (clinicaltrials.gov)
    P4, N=41, Completed, Brigham and Women's Hospital | N=125 --> 41
    Enrollment change
    |
    LEP (Leptin)
    |
    leuprolide acetate for depot suspension
    2ms
    ROSE: Study of Quality of Life and Hormone Levels in Premenopausal Participants With Early Breast Cancer Receiving Triptorelin Plus Additional Cancer Treatment (clinicaltrials.gov)
    P=N/A, N=419, Recruiting, Ipsen | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • HEOR
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA1 mutation • HR positive • HER-2 negative • HR positive + HER-2 negative • BRCA mutation • PTEN mutation + HR positive
    |
    triptorelin
    2ms
    ASCLEPIuS: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer (clinicaltrials.gov)
    P1/2, N=102, Active, not recruiting, University of Michigan Rogel Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DRD (DNA Repair Deficiency)
    |
    DDR • DRD
    |
    Zejula (niraparib) • abiraterone acetate • leuprolide acetate for depot suspension
    2ms
    Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=70, Recruiting, Ohio State University Comprehensive Cancer Center | Not yet recruiting --> Recruiting | Initiation date: Apr 2024 --> Aug 2024
    Enrollment open • Trial initiation date
    |
    Eligard (leuprolide acetate) • Orgovyx (relugolix)
    2ms
    HypoFocal SRT: Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy (clinicaltrials.gov)
    P=N/A, N=36, Recruiting, Insel Gruppe AG, University Hospital Bern | Phase classification: P2 --> P=N/A
    Phase classification
    |
    bicalutamide • triptorelin
    2ms
    LIBELULA: A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (clinicaltrials.gov)
    P3, N=53, Recruiting, Debiopharm International SA | Trial completion date: Sep 2027 --> Dec 2027
    Trial completion date
    |
    triptorelin
    2ms
    PROSTSIZE: Prostatic Size Reduction Following of Leuprorelin Acetate (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Consorci Sanitari de Terrassa | Trial primary completion date: Jul 2024 --> Dec 2024
    Trial primary completion date
    |
    leuprolide acetate for depot suspension
    3ms
    Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia (clinicaltrials.gov)
    P=N/A, N=60, Completed, Seattle Institute for Biomedical and Clinical Research | Active, not recruiting --> Completed
    Trial completion
    |
    goserelin acetate
    3ms
    Adenomyosis and Pregnancy: Levonorgestrel vs. GnRH for Blastocyst Transfer (clinicaltrials.gov)
    P=N/A, N=184, Completed, Zagazig University
    New trial
    |
    triptorelin
    3ms
    Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial) (clinicaltrials.gov)
    P2, N=30, Recruiting, German Oncology Center, Cyprus
    New P2 trial
    |
    goserelin acetate
    3ms
    Intramuscular Mechanisms of Androgen Deprivation-related Sarcopenia (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, Seattle Institute for Biomedical and Clinical Research | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Sep 2023 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    goserelin acetate
    3ms
    Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate (clinicaltrials.gov)
    P3, N=195, Completed, Ipsen | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    triptorelin
    3ms
    Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=14, Recruiting, Roswell Park Cancer Institute | Trial completion date: Apr 2027 --> Oct 2027 | Trial primary completion date: Apr 2026 --> Oct 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    Eligard (leuprolide acetate) • Viadur (leuprorelin implant)
    3ms
    OVELIA: Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (clinicaltrials.gov)
    P3, N=250, Recruiting, Tolmar Inc. | Trial completion date: Apr 2025 --> Apr 2026 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    tamoxifen • letrozole • anastrozole • exemestane • Eligard (leuprolide acetate)
    3ms
    REAL6T: A Study to Observe Demography and the Outcome of Prostate Cancer Patients Treated With 6-month Triptorelin Formulation in Italy (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Ipsen | Trial completion date: Jun 2024 --> Sep 2024 | Trial primary completion date: Jun 2024 --> Sep 2024
    Trial completion date • Trial primary completion date
    |
    triptorelin
    4ms
    Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate (clinicaltrials.gov)
    P3, N=147, Completed, Ipsen | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    triptorelin
    4ms
    GDF-8 Levels in ICSI Cycles (clinicaltrials.gov)
    P=N/A, N=42, Completed, University of Alexandria
    New trial
    4ms
    Potential therapeutic properties of broccoli extract and soy isoflavones on improvement endometriosis and involved oxidative parameters. (PubMed, Horm Mol Biol Clin Investig)
    BE in combination with SI decreased the growth and histopathologic grades of transplanted endometrial implants. These herbal compounds may have the potential therapeutic effect to be used as an alternative medication for the treatment of endometriosis.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    triptorelin
    4ms
    Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer (clinicaltrials.gov)
    P3, N=60, Not yet recruiting, Children's Oncology Group
    New P3 trial
    |
    triptorelin
    5ms
    Efficacy, Metabolism and BMD of the 3-month TP Compared to the 1-month TP in ICPP (clinicaltrials.gov)
    P4, N=134, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
    New P4 trial
    |
    triptorelin
    5ms
    A randomised trial investigating the effectiveness of different durations of maximal androgen deprivation prior to and during definitive radiation therapy for locally advanced carcinoma of the prostate (ACTRN12607000237482)
    P3, N=800, Completed, Trans Tasman Radiation Oncology Group (TROG) | Active, not recruiting --> Completed
    Trial completion • Metastases
    |
    goserelin acetate • flutamide
    5ms
    Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: May 2024 --> May 2025
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide
    5ms
    ARMOR: Adaptions and Resiliency to Multi-Stressor OpeRations (clinicaltrials.gov)
    P4, N=120, Not yet recruiting, Bradley Nindl
    New P4 trial
    |
    goserelin acetate
    6ms
    LIBELULA: A Study to Assess the Efficacy, Safety and Pharmacokinetics of Debio 4326 in Pediatric Participants Receiving Gonadotropin-Releasing Hormone Agonist Therapy for Central Precocious Puberty (clinicaltrials.gov)
    P3, N=53, Recruiting, Debiopharm International SA | Initiation date: Apr 2024 --> Jul 2024
    Trial initiation date
    |
    triptorelin
    7ms
    NRG-GY033: Study to Test the Drug Darolutamide Along With the Drugs Leuprolide Acetate and Exemestane in Patients With Recurrent Ovarian Granulosa Cell Tumors (clinicaltrials.gov)
    P2, N=37, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension • Combination therapy
    |
    ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    exemestane • Eligard (leuprolide acetate) • Nubeqa (darolutamide) • Viadur (leuprorelin implant)
    7ms
    To Assess The Patient Preference for Goserelin Microsphere Versus Goserelin Implant in Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, The First Affiliated Hospital of Xiamen University
    New P2 trial
    |
    goserelin acetate • Baituowei (goserelin acetate sustained-release microspheres for injection)
    7ms
    Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1, N=14, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    Eligard (leuprolide acetate) • Viadur (leuprorelin implant)
    7ms
    The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's (clinicaltrials.gov)
    P2, N=180, Recruiting, Weill Medical College of Cornell University | Trial primary completion date: Feb 2025 --> Dec 2025
    Trial primary completion date
    |
    Eligard (leuprolide acetate)
    7ms
    Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer (clinicaltrials.gov)
    P2, N=104, Recruiting, Fudan University | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial primary completion date
    |
    letrozole • megestrol
    7ms
    Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect (clinicaltrials.gov)
    P=N/A, N=94, Recruiting, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | Not yet recruiting --> Recruiting
    Enrollment open
    |
    leuprolide acetate for depot suspension
    8ms
    PEGASUS: Trial Comparing Irradiation Plus Long Term Adjuvant Androgen Deprivation With GnRH Antagonist Versus GnRH Agonist Plus Flare Protection in Patients With Very High Risk Localized or Locally Advanced Prostate Cancer (clinicaltrials.gov)
    P3, N=885, Active, not recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Nov 2023
    Trial completion date • Trial primary completion date • Metastases
    |
    Firmagon (degarelix)
    8ms
    Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate (clinicaltrials.gov)
    P3, N=195, Active, not recruiting, Ipsen | Recruiting --> Active, not recruiting
    Enrollment closed • Metastases
    |
    triptorelin
    8ms
    YATAGARASU: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Janssen Pharmaceutical K.K. | Trial completion date: May 2024 --> Sep 2025
    Trial completion date • Combination therapy • Metastases
    |
    AR (Androgen receptor)
    |
    AR positive • AR expression
    |
    Erleada (apalutamide) • goserelin acetate
    8ms
    Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, Ohio State University Comprehensive Cancer Center
    New P2 trial
    |
    Eligard (leuprolide acetate) • Orgovyx (relugolix)
    8ms
    Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=25, Recruiting, Washington University School of Medicine | Trial completion date: Jan 2030 --> Jan 2031 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    goserelin acetate